The Differential Effects of Angiotensin II Type 1 Receptor Blockers on Microalbuminuria in Relation to Low-Grade Inflammation in Metabolic Hypertensive Patients

• Published in: American journal of hypertension Vol. 20; no. 5; pp. 565 - 572
• Main Authors: Yano, Yuichiro, Hoshide, Satoshi, Ishikawa, Joji, Noguchi, Chishio, Tukui, Daisuke, Takanori, Hidaka, Tada, Masashi, Kanemaru, Yoshimasa, Yano, Ayako, Ishikawa, Shizukiyo, Shimada, Kazuyuki, Kario, Kazuomi
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01-05-2007; Oxford University Press; Elsevier Science
• Subjects: Aged; Albuminuria - drug therapy; Albuminuria - etiology; Angiotensin II Type 1 Receptor Blockers - therapeutic use; Antihypertensive agents; Arterial hypertension. Arterial hypotension; Benzimidazoles - therapeutic use; Benzoates - therapeutic use; Biological and medical sciences; Blood and lymphatic vessels; Blood Pressure; C-Reactive Protein - analysis; Cardiology. Vascular system; Cardiovascular system; Clinical manifestations. Epidemiology. Investigative techniques. Etiology; Female; HMW adiponectin; Humans; Hypertension - complications; inflammation; Inflammation - drug therapy; Inflammation - etiology; Male; Medical sciences; Metabolic Syndrome - complications; microalbuminuria; Pharmacology. Drug treatments; PPAR gamma - agonists; PPARγ; Telmisartan; Treatment Outcome; microalbuminuria; inflammation; PPARγ; Telmisartan; HMW adiponectin; Human; Hypertension; Urinary system disease; PPARy; Peptide hormone; Albumin; Cardiovascular disease; Inflammation; AT1 angiotensin receptor; Octapeptide; Benzimidazole derivatives; Antihypertensive agent; Angiotensin antagonist; Angiotensin II; Microalbuminuria; Proteinuria
• ISSN: 0895-7061; 1879-1905; 1941-7225
• DOI: 10.1016/j.amjhyper.2006.12.008

A dual angiotensin type 1 receptor blocker (ARB)/peroxisome proliferator-activated receptor-γ (PPARγ) agonist telmisartan may be more useful for microalbuminuria reduction than ARBs with no PPARγ agonistic action. We investigated whether there is a difference between the effects of telmisartan and valsartan with respect to microalbuminuria reduction, and the association with improvement of metabolic features or suppression of the inflammatory state.
Fifty-three patients who had metabolic syndrome and had been taking valsartan were recruited. All of these patients were randomly assigned to replace valsartan by telmisartan (telmisartan group;
n = 30) or to keep taking valsartan (control group;
n = 21). Various parameters were measured at baseline and 12 weeks after randomization.
There were no significant changes in blood pressure (BP), glucose, and lipid parameters between baseline and 12 weeks after randomization in either group. There was a significant increase in high molecular weight adiponectin in the telmisartan group (4.6
v 5.0 μg/mL,
P = .024), whereas there was no significant change in the control group. The reductions of microalbuminuria and high-sensitivity C-reactive protein (hs-CRP) were significant in the telmisartan group (28.1
v 18.9 mg/g
·
Cr and 0.77
v 0.60 mg/L, respectively,
P = .001 and
P = .022), whereas there was no significant change in the control group. The reductions of microalbuminuria and hs-CRP were significantly correlated with each other (γ = 0.413,
P = .003).
The dual ARB/PPARγ agonist telmisartan achieved more microalbuminuria reduction than an ARB with no PPARγ agonistic action, possibly through suppression of the inflammatory state in metabolic hypertensive patients.